Get the Stockscreener App
72.86
4.87%
-3.98
Palvella Therapeutics Inc stock is traded at $72.86, with a volume of 57,450.
It is down -4.87% in the last 24 hours and up +11.13% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$76.84
Open:
$75.315
24h Volume:
57,450
Relative Volume:
0.36
Market Cap:
$808.68M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.54%
1M Performance:
+11.13%
6M Performance:
+198.86%
1Y Performance:
+0.00%
1-Day Range:
$71.55
$76.25
1-Week Range:
$71.55
$83.00
52-Week Range:
$11.17
$83.00
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
73.12 | 849.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.42 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.32 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.61 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.02 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.88 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 - MarketScreener
Palvella Therapeutics to Host Third Quarter 2025 Financial - GlobeNewswire
Why Palvella Therapeutics Inc. stock remains a top recommendationEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Can Palvella Therapeutics Inc. stock deliver consistent earnings growthQuarterly Market Review & Trade Opportunity Analysis - newser.com
Can Palvella Therapeutics Inc. stock rebound after recent weaknessEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Can momentum traders help lift Palvella Therapeutics Inc.July 2025 Pullbacks & Verified Chart Pattern Signals - newser.com
Can Palvella Therapeutics Inc. stock sustain market leadership2025 Market Trends & High Accuracy Buy Signal Tips - newser.com
Trend analysis for Palvella Therapeutics Inc. this week2025 Biggest Moves & Short-Term Trading Alerts - newser.com
How Palvella Therapeutics Inc. stock performs in stagflationQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
What MACD and RSI say about Palvella Therapeutics Inc.Weekly Profit Summary & AI Optimized Trade Strategies - newser.com
Short interest data insights for Palvella Therapeutics Inc.Portfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Tools to monitor Palvella Therapeutics Inc. recovery probabilityJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Will Palvella Therapeutics Inc. stock go up soonProduct Launch & Technical Buy Zone Confirmation - newser.com
How Palvella Therapeutics Inc. (PI6) stock compares with top peersWeekly Stock Recap & Low Drawdown Momentum Ideas - newser.com
Will a bounce in Palvella Therapeutics Inc. offer an exitJuly 2025 Rallies & Safe Capital Allocation Plans - newser.com
How institutional ownership impacts Palvella Therapeutics Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Can Palvella Therapeutics Inc. stock maintain growth trajectoryBear Alert & Momentum Based Trading Ideas - newser.com
Is Palvella Therapeutics Inc. (PI6) stock a good hedge against inflationJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Why Palvella Therapeutics Inc. (PI6) stock is favored by hedge fundsWeekly Stock Recap & Weekly High Conviction Trade Ideas - newser.com
Forecasting Palvella Therapeutics Inc. price range with options dataMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Can Palvella Therapeutics Inc. stock withstand economic slowdown2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
Real time social sentiment graph for Palvella Therapeutics Inc.Earnings Miss & Stock Portfolio Risk Management - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Hits New 52-Week HighWhat's Next? - MarketBeat
Why Palvella Therapeutics Inc. (PI6) stock is upgraded to buyInsider Buying & AI Enhanced Trade Execution Alerts - newser.com
How strong is Palvella Therapeutics Inc. stock balance sheet2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Multi factor analysis applied to Palvella Therapeutics Inc.Earnings Miss & AI Driven Stock Price Forecasts - newser.com
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.35%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):